{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:24:14Z","timestamp":1776479054246,"version":"3.51.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11910-022-01175-w","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T15:02:43Z","timestamp":1644418963000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-727X","authenticated-orcid":false,"given":"H\u00e5kan","family":"Ashina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"issue":"6","key":"1175_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1474-4422(21)00094-6","volume":"20","author":"H Ashina","year":"2021","unstructured":"Ashina H, Eigenbrodt AK, Seifert T, Sinclair AJ, Scher AI, Schytz HW, Lee MJ, De Icco R, Finkel AG, Ashina M. Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. Lancet Neurol. 2021;20(6):460\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(21)00094-6.","journal-title":"Lancet Neurol"},{"key":"1175_CR2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018; 38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"issue":"6","key":"1175_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0333102420909865","volume":"40","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Al-Khazali HM, Ashina S, Jensen RH, Amin FM, Ashina M, Schytz HW. Persistent post-traumatic headache attributed to mild traumatic brain injury: deep phenotyping and treatment patterns. Cephalalgia. 2020;40(6):554\u201364. https:\/\/doi.org\/10.1177\/0333102420909865.","journal-title":"Cephalalgia"},{"issue":"1","key":"1175_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10194-020-01202-6","volume":"21","author":"H Ashina","year":"2020","unstructured":"Ashina H, Iljazi A, Amin FM, Ashina M, Lipton RB, Schytz HW. Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. J Headache Pain. 2020;21(1):134. https:\/\/doi.org\/10.1186\/s10194-020-01202-6.","journal-title":"J Headache Pain"},{"issue":"8","key":"1175_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/0333102412445224","volume":"32","author":"S Lucas","year":"2012","unstructured":"Lucas S, Hoffman JM, Bell KR, Walker W, Dikmen S. Characterization of headache after traumatic brain injury. Cephalalgia. 2012;32(8):600\u20136. https:\/\/doi.org\/10.1177\/0333102412445224.","journal-title":"Cephalalgia"},{"issue":"2","key":"1175_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0333102413499645","volume":"34","author":"S Lucas","year":"2014","unstructured":"Lucas S, Hoffman JM, Bell KR, Dikmen S. A prospective study of prevalence and characterization of headache following mild traumatic brain injury. Cephalalgia. 2014;34(2):93\u2013102. https:\/\/doi.org\/10.1177\/0333102413499645.","journal-title":"Cephalalgia"},{"issue":"6","key":"1175_CR7","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/head.12123","volume":"53","author":"B Theeler","year":"2013","unstructured":"Theeler B, Lucas S, Riechers RG 2nd, Ruff RL. Post-traumatic headaches in civilians and military personnel: a comparative, clinical review. Headache. 2013;53(6):881\u2013900. https:\/\/doi.org\/10.1111\/head.12123.","journal-title":"Headache"},{"issue":"6","key":"1175_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/head.13311","volume":"58","author":"S Lucas","year":"2018","unstructured":"Lucas S, Ahn AH. Posttraumatic headache: classification by symptom-based clinical profiles. Headache. 2018;58(6):873\u201382. https:\/\/doi.org\/10.1111\/head.13311.","journal-title":"Headache"},{"issue":"4","key":"1175_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0333102420970188","volume":"41","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ. Post-traumatic headache due to mild traumatic brain injury: current knowledge and future directions. Cephalalgia. 2021;41(4):464\u201371. https:\/\/doi.org\/10.1177\/0333102420970188.","journal-title":"Cephalalgia"},{"issue":"3","key":"1175_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/head.14084","volume":"61","author":"H Ashina","year":"2021","unstructured":"Ashina H, Moskowitz MA. Shared biological foundations of post-traumatic headache and migraine. Headache. 2021;61(3):558\u20139. https:\/\/doi.org\/10.1111\/head.14084.","journal-title":"Headache"},{"issue":"10","key":"1175_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11916-018-0720-6","volume":"22","author":"D Bree","year":"2018","unstructured":"Bree D, Levy D. Strides toward better understanding of post-traumatic headache pathophysiology using animal models. Curr Pain Headache Rep. 2018;22(10):67. https:\/\/doi.org\/10.1007\/s11916-018-0720-6.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1175_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s10194-019-1051-7","volume":"20","author":"EL Larsen","year":"2019","unstructured":"\u2022 Larsen EL, Ashina H, Iljazi A, Al-Khazali HM, Seem K, Ashina M, Ashina S, Schytz HW. Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. J Headache Pain. 2019;20(1):98. https:\/\/doi.org\/10.1186\/s10194-019-1051-7. (A systematic review that summarizes the evidence for pharmacologic treatment of acute and persistent PTH and outlines the need for controlled trials.)","journal-title":"J Headache Pain"},{"issue":"11","key":"1175_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11910-016-0697-7","volume":"16","author":"MT Minen","year":"2016","unstructured":"Minen MT, Boubour A, Walia H, Barr W. Post-concussive syndrome: a focus on post-traumatic headache and related cognitive, psychiatric, and sleep issues. Curr Neurol Neurosci Rep. 2016;16(11):100. https:\/\/doi.org\/10.1007\/s11910-016-0697-7.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"1175_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-021-01287-7","volume":"22","author":"H Ashina","year":"2021","unstructured":"Ashina H, Al-Khazali HM, Iljazi A, Ashina S, Amin FM, Lipton RB, Schytz HW. Psychiatric and cognitive comorbidities of persistent post-traumatic headache attributed to mild traumatic brain injury. J Headache Pain. 2021;22(1):83. https:\/\/doi.org\/10.1186\/s10194-021-01287-7.","journal-title":"J Headache Pain"},{"issue":"4","key":"1175_CR15","doi-asserted-by":"publisher","first-page":"CD008041","DOI":"10.1002\/14651858.CD008041.pub3","volume":"2013","author":"V Kirthi","year":"2013","unstructured":"Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008041. https:\/\/doi.org\/10.1002\/14651858.CD008041.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"1175_CR16","doi-asserted-by":"publisher","first-page":"CD008783","DOI":"10.1002\/14651858.CD008783.pub3","volume":"2013","author":"S Derry","year":"2013","unstructured":"Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008783. https:\/\/doi.org\/10.1002\/14651858.CD008783.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"4","key":"1175_CR17","doi-asserted-by":"publisher","first-page":"CD008039","DOI":"10.1002\/14651858.CD008039.pub3","volume":"2013","author":"R Rabbie","year":"2013","unstructured":"Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008039. https:\/\/doi.org\/10.1002\/14651858.CD008039.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"1175_CR18","doi-asserted-by":"publisher","first-page":"CD011888","DOI":"10.1002\/14651858.CD011888.pub2","volume":"1","author":"S Derry","year":"2017","unstructured":"Derry S, Wiffen PJ, Moore RA. Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2017;1(1):CD011888. https:\/\/doi.org\/10.1002\/14651858.CD011888.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"1175_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1090-3801(02)00094-0","volume":"7","author":"F Kubitzek","year":"2003","unstructured":"Kubitzek F, Ziegler G, Gold MS, Liu JM, Ionescu E. Low-dose diclofenac potassium in the treatment of episodic tension-type headache. Eur J Pain. 2003;7(2):155\u201362. https:\/\/doi.org\/10.1016\/S1090-3801(02)00094-0.","journal-title":"Eur J Pain"},{"issue":"7","key":"1175_CR20","doi-asserted-by":"publisher","first-page":"CD011474","DOI":"10.1002\/14651858.CD011474.pub2","volume":"2015","author":"S Derry","year":"2015","unstructured":"Derry S, Wiffen PJ, Moore RA, Bendtsen L. Ibuprofen for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2015;2015(7):CD011474. https:\/\/doi.org\/10.1002\/14651858.CD011474.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"19","key":"1175_CR21","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"AM Migraine","year":"2020","unstructured":"Migraine AM. N Engl J Med. 2020;383(19):1866\u201376. https:\/\/doi.org\/10.1056\/NEJMra1915327.","journal-title":"N Engl J Med"},{"issue":"1","key":"1175_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-021-00257-2","volume":"7","author":"S Ashina","year":"2021","unstructured":"Ashina S, Mitsikostas DD, Lee MJ, Yamani N, Wang SJ, Messina R, Ashina H, Buse DC, Pozo-Rosich P, Jensen RH, Diener HC, Lipton RB. Tension-type headache Nat Rev Dis Primers. 2021;7(1):24. https:\/\/doi.org\/10.1038\/s41572-021-00257-2.","journal-title":"Tension-type headache Nat Rev Dis Primers"},{"issue":"4","key":"1175_CR23","doi-asserted-by":"publisher","first-page":"CD008040","DOI":"10.1002\/14651858.CD008040.pub3","volume":"2013","author":"S Derry","year":"2013","unstructured":"Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013;2013(4):CD008040. https:\/\/doi.org\/10.1002\/14651858.CD008040.pub3.","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"1175_CR24","doi-asserted-by":"publisher","first-page":"CD011889","DOI":"10.1002\/14651858.CD011889.pub2","volume":"2016","author":"G Stephens","year":"2016","unstructured":"Stephens G, Derry S, Moore RA. Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev. 2016;2016(6):CD011889. https:\/\/doi.org\/10.1002\/14651858.CD011889.pub2.","journal-title":"Cochrane Database Syst Rev."},{"key":"1175_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15103","author":"HC Diener","year":"2021","unstructured":"Diener HC, Gaul C, Lehmacher W, Weiser T. Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: a systemic review and meta-analysis of randomised placebo-controlled trials. Eur J Neurol. 2021. https:\/\/doi.org\/10.1111\/ene.15103.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1175_CR26","doi-asserted-by":"publisher","first-page":"CD009108","DOI":"10.1002\/14651858.CD009108.pub2","volume":"2014","author":"CJ Derry","year":"2014","unstructured":"Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014;2014(5):CD009108. https:\/\/doi.org\/10.1002\/14651858.CD009108.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"10283","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ, Terwindt GM, Halker Singh R, Tassorelli C, Do TP, Mitsikostas DD, Dodick DW. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(20)32342-4.","journal-title":"Lancet"},{"issue":"23","key":"1175_CR28","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813049.","journal-title":"N Engl J Med"},{"issue":"10200","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X.","journal-title":"Lancet"},{"issue":"8","key":"1175_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, Pozo-Rosich P, Martelletti P, Ducros A, Lant\u00e9ri-Minet M, Braschinsky M, Del Rio MS, Daniel O, \u00d6zge A, Mammadbayli A, Arons M, Skorobogatykh K, Romanenko V, Terwindt GM, Paemeleire K, Sacco S, Reuter U, Lampl C, Schytz HW, Katsarava Z, Steiner TJ, Ashina M. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501\u201314. https:\/\/doi.org\/10.1038\/s41582-021-00509-5.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"1175_CR31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","volume":"18","author":"HC Diener","year":"2019","unstructured":"Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019;18(9):891\u2013902. https:\/\/doi.org\/10.1016\/S1474-4422(19)30146-2.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1175_CR32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102420938652","volume":"40","author":"E Navratilova","year":"2020","unstructured":"Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia. 2020;40(9):892\u2013902. https:\/\/doi.org\/10.1177\/0333102420938652.","journal-title":"Cephalalgia"},{"issue":"7","key":"1175_CR33","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102411402367","volume":"31","author":"ID Meng","year":"2011","unstructured":"Meng ID, Dodick D, Ossipov MH, Porreca F. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011;31(7):851\u201360. https:\/\/doi.org\/10.1177\/0333102411402367.","journal-title":"Cephalalgia"},{"issue":"10268","key":"1175_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)32544-7.","journal-title":"Lancet"},{"key":"1175_CR35","doi-asserted-by":"publisher","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695\u2013706. doi: https:\/\/doi.org\/10.1056\/NEJMoa2035908.","DOI":"10.1056\/NEJMoa2035908"},{"issue":"8","key":"1175_CR36","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18(8):795\u2013804. https:\/\/doi.org\/10.1016\/S1474-4422(19)30185-1.","journal-title":"Lancet Neurol"},{"issue":"8148","key":"1175_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0140-6736(79)92692-8","volume":"2","author":"MA Moskowitz","year":"1979","unstructured":"Moskowitz MA, Reinhard JF Jr, Romero J, Melamed E, Pettibone DJ. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet. 1979;2(8148):883\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(79)92692-8.","journal-title":"Lancet"},{"issue":"2","key":"1175_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ana.410160202","volume":"16","author":"MA Moskowitz","year":"1984","unstructured":"Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984;16(2):157\u201368. https:\/\/doi.org\/10.1002\/ana.410160202.","journal-title":"Ann Neurol"},{"issue":"10283","key":"1175_CR39","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)32162-0","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Terwindt GM, Al-Karagholi MA, de Boer I, Lee MJ, Hay DL, Schulte LH, Hadjikhani N, Sinclair AJ, Ashina H, Schwedt TJ, Goadsby PJ. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;397(10283):1496\u2013504. https:\/\/doi.org\/10.1016\/S0140-6736(20)32162-0.","journal-title":"Lancet"},{"issue":"10","key":"1175_CR40","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2018.1675","volume":"75","author":"ALH Vollesen","year":"2018","unstructured":"Vollesen ALH, Snoer A, Beske RP, Guo S, Hoffmann J, Jensen RH, Ashina M. Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial. JAMA Neurol. 2018;75(10):1187\u201397. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1675.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1175_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543\u201359. https:\/\/doi.org\/10.1097\/j.pain.0000000000000831.","journal-title":"Pain"},{"issue":"10","key":"1175_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41582-019-0243-8","volume":"15","author":"H Ashina","year":"2019","unstructured":"Ashina H, Porreca F, Anderson T, Amin FM, Ashina M, Schytz HW, Dodick DW. Post-traumatic headache: epidemiology and pathophysiological insights. Nat Rev Neurol. 2019;15(10):607\u201317. https:\/\/doi.org\/10.1038\/s41582-019-0243-8.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1175_CR43","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0333102420940681","volume":"40","author":"MA Al-Karagholi","year":"2020","unstructured":"Al-Karagholi MA, Ghanizada H, Nielsen CAW, Skandarioon C, Snellman J, Lopez Lopez C, Hansen JM, Ashina M. Opening of BKCa channels alters cerebral hemodynamic and causes headache in healthy volunteers. Cephalalgia. 2020;40(11):1145\u201354. https:\/\/doi.org\/10.1177\/0333102420940681.","journal-title":"Cephalalgia"},{"issue":"10","key":"1175_CR44","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1097\/j.pain.0000000000002238","volume":"162","author":"MA Al-Karagholi","year":"2021","unstructured":"Al-Karagholi MA, Ghanizada H, Waldorff Nielsen CA, Skandarioon C, Snellman J, Lopez-Lopez C, Hansen JM, Ashina M. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain. 2021;162(10):2512\u201320. https:\/\/doi.org\/10.1097\/j.pain.0000000000002238.","journal-title":"Pain"},{"issue":"9","key":"1175_CR45","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1093\/brain\/awz199","volume":"142","author":"MA Al-Karagholi","year":"2019","unstructured":"Al-Karagholi MA, Hansen JM, Guo S, Olesen J, Ashina M. Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain. 2019;142(9):2644\u201354. https:\/\/doi.org\/10.1093\/brain\/awz199.","journal-title":"Brain"},{"issue":"6","key":"1175_CR46","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0333102420981688","volume":"41","author":"CM Kopruszinski","year":"2021","unstructured":"Kopruszinski CM, Turnes JM, Swiokla J, Weinstein TJ, Schwedt TJ, Dodick DW, Anderson T, Navratilova E, Porreca F. CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. Cephalalgia. 2021;41(6):749\u201359. https:\/\/doi.org\/10.1177\/0333102420981688.","journal-title":"Cephalalgia"},{"issue":"14","key":"1175_CR47","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1177\/0333102419877662","volume":"39","author":"E Navratilova","year":"2019","unstructured":"\u2022\u2022 Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J, Remeniuk B, Schwedt T, Anderson T, Dodick D, Porreca F. CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia. 2019;39(14):1762\u201375. https:\/\/doi.org\/10.1177\/0333102419877662. (This animal study demonstrated that early and continuous blockade of CGRP signaling can prevent cutaneous allodynia in concussed rodents.)","journal-title":"Cephalalgia"},{"issue":"7","key":"1175_CR48","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1177\/0333102420907597","volume":"40","author":"D Bree","year":"2020","unstructured":"Bree D, Mackenzie K, Stratton J, Levy D. Enhanced post-traumatic headache-like behaviors and diminished contribution of peripheral CGRP in female rats following a mild closed head injury. Cephalalgia. 2020;40(7):748\u201360. https:\/\/doi.org\/10.1177\/0333102420907597.","journal-title":"Cephalalgia"},{"issue":"2","key":"1175_CR49","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/0333102416681571","volume":"38","author":"D Bree","year":"2018","unstructured":"Bree D, Levy D. Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: implications for mechanisms of post-traumatic headache. Cephalalgia. 2018;38(2):246\u201358. https:\/\/doi.org\/10.1177\/0333102416681571.","journal-title":"Cephalalgia"},{"issue":"8","key":"1175_CR50","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1089\/neu.2015.4087","volume":"33","author":"BV Daiutolo","year":"2016","unstructured":"Daiutolo BV, Tyburski A, Clark SW, Elliott MB. Trigeminal pain molecules, allodynia, and photosensitivity are pharmacologically and genetically modulated in a model of traumatic brain injury. J Neurotrauma. 2016;33(8):748\u201360. https:\/\/doi.org\/10.1089\/neu.2015.4087.","journal-title":"J Neurotrauma"},{"issue":"6","key":"1175_CR51","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/ana.25915","volume":"88","author":"H Ashina","year":"2020","unstructured":"\u2022\u2022 Ashina H, Iljazi A, Al-Khazali HM, Christensen CE, Amin FM, Ashina M, Schytz HW. Hypersensitivity to calcitonin gene-related peptide in post-traumatic headache. Ann Neurol. 2020;88(6):1220\u20138. https:\/\/doi.org\/10.1002\/ana.25915. (This study found that intravenous infusion of CGRP induces headache with migraine-like features in patients with persistent PTH who reported no pre-existing migraine.)","journal-title":"Ann Neurol"},{"issue":"1","key":"1175_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10194-020-01136-z","volume":"21","author":"H Ashina","year":"2020","unstructured":"\u2022\u2022 Ashina H, Iljazi A, Al-Khazali HM, Eigenbrodt AK, Larsen EL, Andersen AM, Hansen KJ, Br\u00e4uner KB, M\u00f8rch-Jessen T, Chaudhry B, Antic S, Christensen CE, Ashina M, Amin FM, Schytz HW. Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain. 2020;21(1):62. https:\/\/doi.org\/10.1186\/s10194-020-01136-z. (This 12-week open-label trial reported that erenumab provided a \u226550% reduction in moderate-to-severe headache days in 28% of patients with persistent PTH.)","journal-title":"J Headache Pain"},{"issue":"5\u20136","key":"1175_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/milmed\/usaa391","volume":"186","author":"MD Zirovich","year":"2021","unstructured":"\u2022 Zirovich MD, Pangarkar SS, Manh C, Chen L, Vangala S, Elashoff DA, Izuchukwu IS. Botulinum toxin type A for the treatment of post-traumatic headache: a randomized, placebo-controlled, cross-over study. Mil Med. 2021;186(5\u20136):493\u20139. https:\/\/doi.org\/10.1093\/milmed\/usaa391. (A small randomized placebo-controlled trial that demonstrated the effectiveness of botulinum toxin type A for prevention of persistent PTH.)","journal-title":"Mil Med"},{"key":"1175_CR54","doi-asserted-by":"publisher","unstructured":"Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35\u201342; discussion 42\u20133. doi: https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04007.x..","DOI":"10.1111\/j.1526-4610.2004.04007.x"},{"key":"1175_CR55","unstructured":"Egilius L.H. Spierings, Stephen Silberstein, Umer Najib, Juline Bryson, Steve Barash, Jiang Li, Andrew Ahn. A phase 2 study of fremanezumab as a treatment for posttraumatic headache in adult patients (1588). Neurology. 2021; 96 (15 Supplement)."},{"issue":"9","key":"1175_CR56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpain.2009.06.012","volume":"10","author":"A Latremoliere","year":"2009","unstructured":"Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895\u2013926. https:\/\/doi.org\/10.1016\/j.jpain.2009.06.012.","journal-title":"J Pain"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01175-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T10:31:59Z","timestamp":1649673119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01175-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01175-w","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"1 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David W. Dodick reports the following conflicts within the past 12\u00a0months: consulting: Amgen, Atria, Cerecin, Cooltech, Ctrl M, Allergan, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, Perfood, Praxis, AYYA Biosciences, Revance. Honoraria: Vector psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, WebMD Health\/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Stock Options\/Shareholder\/Patents\/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (Options), Theranica (Options), Second Opinion\/Mobile Health (Options), Epien (Options\/Board), Nocira (options), Matterhorn (Shares\/Board), Ontologics (Shares\/Board), King-Devick Technologies (Options\/Board), Precon Health (Options\/Board), AYYA Biosciences (Options). Patent 17189376.1\u20131466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis. H\u00e5kan Ashina reports no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors have read the final version of the manuscript and approve its content for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}